for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.A

Latest Trade

7.79USD

Change

-0.36(-4.36%)

Volume

3,165

Today's Range

7.74

 - 

8.06

52 Week Range

6.11

 - 

18.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.14
Open
8.06
Volume
3,165
3M AVG Volume
97.40
Today's High
8.06
Today's Low
7.74
52 Week High
18.96
52 Week Low
6.11
Shares Out (MIL)
210.36
Market Cap (MIL)
1,712.31
Forward P/E
-6.26
Dividend (Yield %)
--

Next Event

Inovio Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)

Latest Developments

More

Inovio Receives Authorization To Conduct Phase 3 Efficacy Trial Of COVID-19 DNA Vaccine Candidate

Inovio Reports Second Quarter 2021 Financial Results

Inovio Expands Partnership With Advaccine To Conduct Global Phase 3 Trial OF COVID-19 VACCINE

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry

Biotechnology & Drugs

Contact Info

6769 Mesa Ridge Rd

SAN DIEGO, CA

92121-2995

United States

+1.858.4103134

http://www.inovio.com/

Executive Leadership

Simon X. Benito

Independent Chairman of the Board

Jong Joseph Kim

President, Chief Executive Officer, Director

Jay P. Shepard

Independent Vice Chairman of the Board

Peter D. Kies

Chief Financial Officer

Jacqueline Elizabeth Shea

Chief Operating Officer

Key Stats

2.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.050

2019

-1.210

2020

-1.070

2021(E)

-1.301
Price To Earnings (TTM)
--
Price To Sales (TTM)
265.03
Price To Book (MRQ)
3.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.86
LT Debt To Equity (MRQ)
2.86
Return on Investment (TTM)
-29.11
Return on Equity (TTM)
-26.59

Latest News

Latest News

Inovio to start COVID-19 vaccine trial after Brazil regulator's nod

Inovio Pharmaceuticals Inc said on Thursday it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil's regulatory agency.

Inovio to start COVID-19 vaccine trial after getting Brazil regulator approval

Inovio Pharmaceuticals Inc said on Thursday it received authorization from Brazil's regulatory agency to conduct mid-to-late stage trial of its COVID-19 vaccine. (Reporting by Mrinalika Roy in Bengaluru)

Inovio focused on launching global COVID-19 vaccine trial next month - CEO

Inovio Pharmaceuticals Inc is focused on launching the global late-stage trial of its COVID-19 vaccine candidate next month, chief executive Joseph Kim said in a call, with the drug developer expecting trial data in the first half of next year.

Inovio focused on launching global COVID-19 vaccine trial next month - CEO

Inovio Pharmaceuticals Inc is focused on launching the global late-stage trial of its COVID-19 vaccine candidate next month, Chief Executive Officer Joseph Kim said during a post-earnings call on Monday.

Inovio expands partnership with Advaccine for COVID-19 vaccine study

Inovio Pharmaceuticals Inc on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate, expected to start in the summer.

Inovio expands partnership with Advaccine for COVID-19 vaccine study

Inovio Pharmaceuticals Inc on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate.

Inovio to start global late-stage COVID-19 vaccine trial this summer

Inovio Pharmaceuticals plans to begin a global late-stage trial of its COVID-19 vaccine candidate this summer, the company said on Monday, a month after the U.S. government pulled the funding for further studies of the drug.

BRIEF-Inovio Pharmaceuticals Exec Says The Ex-Us Trial For Covid-19 Vaccine Candidate Is Not Impacted By The Current Phase 3 Partial Clinical Hold- Conf. Call

* EXEC SAYS THE EX-US TRIAL FOR COVID-19 VACCINE CANDIDATE IS NOT IMPACTED BY THE CURRENT PHASE 3 PARTIAL CLINICAL HOLD- CONF. CALL

Inovio to start global late-stage COVID-19 vaccine trial this summer

Inovio Pharmaceuticals said on Monday it plans to start a global late-stage trial for its COVID-19 vaccine candidate, INO-4800, this summer. (https://refini.tv/3uAVRFV)

Inovio says COVID-19 vaccine candidate safe, effective in mid-stage trial

Inovio Pharmaceuticals Inc said its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial, sending the drug developer's shares up over 3%.

Inovio says vaccine candidate safe, effective in clinical trial

Inovio Pharmaceuticals on Monday said its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the coronavirus in all tested age groups in a mid-stage clinical trial. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)

Inovio considers moving COVID-19 vaccine trial overseas as U.S. ends funding

Inovio Pharmaceuticals said on Friday the U.S. government pulled the funding for a late-stage study testing its COVID-19 vaccine candidate and that it would now pursue conducting the trial largely outside the country.

UPDATE 3-Inovio considers moving COVID-19 vaccine trial overseas as U.S. ends funding

Inovio Pharmaceuticals said on Friday the U.S. government pulled the funding for a late-stage study testing its COVID-19 vaccine candidate and that it would now pursue conducting the trial largely outside the country.

Inovio expects COVID-19 vaccine U.S. trial data by early second quarter

U.S. vaccine developer Inovio Pharmaceuticals Inc said on Monday it had completed Phase II enrolment for a mid-to-late stage U.S. trial of its COVID-19 vaccine candidate and expects to report data early in the second quarter.

BRIEF-Inovio Testing Potential Usage Of COVID-19 Vaccine Candidate As Seasonal Booster: Conf Call

* INOVIO EXPECTS TO COMPLETE PHASE TWO SEGMENT OF MID-TO-LATE STAGE U.S. TRIAL OF COVID-19 VACCINE CANDIDATE IN EARLY SECOND QUARTER: CONF CALL

Inovio developing vaccines to target coronavirus variants

U.S. drug developer Inovio Pharmaceuticals Inc said on Monday it was developing next-generation COVID-19 vaccine candidates that could be tailored to the known and potentially the unknown SARS-CoV-2 variants.

Inovio expects to begin late-stage COVID-19 vaccine study in second quarter (Jan. 4)

(In Jan. 4 story, corrects paragraph 2 to say INO-4800 is being tested in three mid-stage trials, including one in South Korea, not two trials. The error was repeated in previous versions of the story)

Inovio partners with Advaccine to commercialize COVID-19 vaccine in China

Inovio Pharmaceuticals Inc has partnered with Advaccine Biopharmaceuticals Suzhou Co Ltd to manufacture and commercialize its COVID-19 vaccine candidate in China, the companies said on Monday.

Inovio doses first volunteer as part of its COVID-19 vaccine mid-stage trial

Inovio Pharmaceuticals Inc said on Monday it has dosed the first participant in a mid-stage clinical trial testing its COVID-19 vaccine candidate, INO-4800.

Inovio doses first participant of COVID-19 vaccine mid-stage trial

Inovio Pharmaceuticals Inc said on Monday it has dosed the first participant in a mid-stage clinical trial testing its COVID-19 vaccine candidate, INO-4800.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up